Zencore Biologics Co., Ltd., headquartered in Lin-gang New Area, Shanghai Pilot Free Trade Zone, China, is an independent Contract Development and Manufacturing Organization (CDMO). Zencore is solely focused on providing CDMO services and does not engage in or invest in any business as a Marketing Authorization Holder (MAH) of pharmaceutical products.
Zencore supports biopharmaceutical companies across all stages of clinical development and commercial manufacturing. Leveraging deep industry experience and strong technical expertise, Zencore delivers comprehensive end-to-end CMC (Chemistry, Manufacturing, and Controls) services. These include developability assessments, stable cell line development, process and analytical development, method transfer and validation, drug substance manufacturing, drug product fill/finish/packaging, lot release testing, stability studies, regulatory submission support, as well as catalog and customized development and production of mammalian cell culture media.
Zencore operates two state-of-the-art CDMO facilities totaling 600,000 square feet. Pilot-scale production is supported by 4×200L and 1×500L single-use bioreactors. For commercial GMP manufacturing, Zencore offers advanced production suites equipped with 3×500L single-use, 3×2,000L single-use, and 3×5,000L stainless steel bioreactors. These capabilities are fully integrated with downstream purification, formulation, and fill/finish lines to meet global regulatory and quality standards.
21st century is the era of biotechnology and biopharmaceutical industries. Rapid advancements in life sciences, technologies, and healthcare have brought numerous previously untreatable diseases under control with a significant improvement in patient survival rates and quality of life. These changes have presented many opportunities and challenges for CROs and CDMOs to support the R&D of biopharmaceutical industries. With the aspiration to contribute to a healthier world, Zencore Biologics was established.
A purposeful enterprise requires a group of professionals with ambition, vision, and passion. Zencore is privileged to work with many experienced entrepreneurs, talented scientists, and skilled engineers who share our common aspirations and values.
Since its establishment in 2017, Zencore has continuously innovated in technologies and bioprocesses to improve operational efficiencies. We have been at the forefront of supporting the growth of biopharmaceutical R&D and have earned a good reputation among our global clients.
With a strong belief in 'Of the people, by the people, for the people,' we strive to unlock immense potential and creativity. Guided by our principles of 'Pursue the Truth, Commit to the Utmost, and Strive for Excellence,' we collaborate with our clients to build a better and healthier world.
Jianxin Chen ,CEO of Zencore Biologics Co., Ltd.
Learn More...
Since its establishment in 2017, Zencore Biologics has become the industry leader in large-scale mammalian cell culture technology. Our team has achieved the record high expression level in the fed-batch culture process for antibody production, which currently stands at 15 g/L.
To date, Zencore Biologics has helped customers complete 38 IND and 4 BLA projects, with more than 200 project experiences overall.
Guided by our values to‘Pursue the Truth, Commit the Utmost, and Strive for Excellence’, we are dedicated to providing the best and most cost-effective solutions for our customers.
